Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.45 |
| ▸ | RARA | P10276 | 6/20 | 0.45 |
| ▸ | RARG | P13631 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941525 | 1.00 | RARB (0.45) | RARBRARARARGEGFRRXRA | |
| SCHEMBL8177006 | 0.92 | EGFR (0.39) | RARBRARARARGEGFRALDH1A1 | |
| SCHEMBL1683959 | 0.89 | RARB (0.48) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL1683960 | 0.89 | RARB (0.48) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL7930726 | 0.85 | RARB (0.47) | RARBRARARARGEGFRRXRA | |
| SCHEMBL6430338 | 0.83 | RARB (0.53) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL6430311 | 0.83 | RARB (0.53) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL7930761 | 0.81 | RARB (0.51) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL8175733 | 0.81 | TDP1 (0.43) | RARBRARARARGALDH1A1SMN1; SMN2 | |
| SCHEMBL1683971 | 0.79 | RARB (0.45) | RARBRARARARGEGFRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| EP-1255543-B1 | USE OF RETINOID-TYPE COMPOUNDS AS ANTIBACTERIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | GALDERMA RES & DEV (FR) | 2010-09-01 | — | — | EP | claimed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-8969544-B2 | Combined use of PRAME inhibitors and HDAC inhibitors | BERNARDS RENé (NL) | 2015-03-03 | — | — | US | disclosed |
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | BERNARDS RENE (NL) | 2013-05-16 | — | — | US | disclosed |
| US-7928081-B2 | biodrugs contains siRNA or vector encoding siRNA, including a retinoid as antitumor agents, anticarcinogenic agents | Bernards, Rene (NL) | 2011-04-19 | — | — | US | disclosed |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | BERNARDS RENE | 2008-05-22 | — | — | US | disclosed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123327-A1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | HDAC5, HDAC8, HDAC11 | RARB 14/4885RARA 29/4885RARG 24/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARB 987/4885RARA 1211/4885RARG 744/4885 |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | HDAC5, HDAC8, HDAC11 | RARB 14/4885RARA 29/4885RARG 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.